{
    "clinical_study": {
        "@rank": "11654", 
        "arm_group": [
            {
                "arm_group_label": "QPI-1007 Injection", 
                "arm_group_type": "Active Comparator", 
                "description": "single intravitreal (IVT) injection of QPI-1007"
            }, 
            {
                "arm_group_label": "Control", 
                "arm_group_type": "Sham Comparator", 
                "description": "Placebo (Sham injection procedure)"
            }
        ], 
        "brief_summary": {
            "textblock": "This study will assess any side effects that may occur when QPI-1007 is injected into the\n      eye in subjects with acute primary angle-closure glaucoma, as well as how long it takes for\n      the body to clear the drug. This study will also test whether QPI-1007, injected into the\n      eye, helps prevent both structural damage of the nerve tissue in the eye and the loss of\n      visual function in subjects with acute primary angle-closure glaucoma."
        }, 
        "brief_title": "Phase IIA Double-Masked Randomized Sham-Controlled Trial of QPI-1007 Delivered by a Single Intravitreal Injection to Subjects With Acute Primary Angle-Closure Glaucoma (APACG)", 
        "completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Glaucoma, Angle-closure, Primary, Acute", 
        "condition_browse": {
            "mesh_term": [
                "Glaucoma", 
                "Glaucoma, Angle-Closure"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a Phase IIa double-masked, single dose, randomized, sham-controlled study evaluating\n      the safety and tolerability, and pharmacokinetics of QPI-1007 versus Control (sham\n      procedure) in subjects with an acute attack of primary angle-closure glaucoma.\n\n      Subjects will be randomized at a ratio of 1:1 into one of two study arms: 1.5 QPI-1007 arm\n      or Control arm (sham procedure).  The study will enroll approximately 30 subjects into each\n      arm. Randomization will be stratified by time from symptom onset to the study drug\n      administration or sham procedure (\u226472 hours and >72 hours)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Males and females aged at least 40 years or older.\n\n          -  Onset of symptoms of an acute attack of primary angle-closure in the study eye within\n             the 120 hours prior to the planned study drug administration.\n\n          -  Best-corrected visual acuity (BCVA) 20/40 or better in the study eye after resolution\n             of the acute attack.\n\n          -  Received successful treatment for the acute attack of angle-closure, and have\n             undergone laser iridotomy with intraocular pressure in the study eye <25mm Hg.\n\n          -  Sufficiently clear ocular media and adequate pupil dilation to allow the optic nerve\n             and fovea to be visualized and assessed in the study eye.\n\n          -  Female subjects must be:  (1) post menopausal, (2) surgically sterile, or (3) using\n             an effective means of contraception.\n\n        Exclusion Criteria:\n\n          -  Previously diagnosed with glaucoma in either eye.\n\n          -  The time planned for study drug administration is more than 120 hours from the onset\n             of the symptoms.\n\n          -  History of chronic angle-closure in either eye.\n\n          -  Secondary angle-closure/secondary angle-closure glaucoma in the study eye.\n\n          -  Monocular subjects.\n\n          -  Prior incisional intraocular surgery.\n\n          -  Inability to perform a reliable visual field test on Day 0 in the study eye.\n\n          -  History of panretinal photocoagulation or macular laser photocoagulation in the study\n             eye.\n\n          -  History of active malignancy within the last 5 years (however, non facial, basal cell\n             carcinoma is allowed).\n\n          -  History of myocardial infarction within the last 6 months.\n\n          -  Received any drugs known to cause optic nerve or retinal toxicity within 14 days\n             prior to dosing.\n\n          -  Women who are pregnant or lactating.\n\n          -  Participating in a concurrent interventional study with the last intervention\n             occurring within 30 days prior to planned dosing with QPI-1007."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "40 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 11, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01965106", 
            "org_study_id": "QRK208"
        }, 
        "intervention": [
            {
                "arm_group_label": "QPI-1007 Injection", 
                "description": "1.5 mg QPI-1007 Injection", 
                "intervention_name": "QPI-1007 Injection", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Control", 
                "description": "Sham injection procedure", 
                "intervention_name": "(including placebo)", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Glaucoma, Angle-Closure", 
            "Glaucoma, Closed-Angle", 
            "Primary angle closure", 
            "Acute angle closure", 
            "Acute angle-closure glaucoma"
        ], 
        "lastchanged_date": "May 21, 2014", 
        "location": [
            {
                "contact": {
                    "email": "jgrijalv@uci.edu", 
                    "last_name": "Jeff Grijalva", 
                    "phone": "714-456-7741"
                }, 
                "facility": {
                    "address": {
                        "city": "Orange", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92868"
                    }, 
                    "name": "The Gavin Herbert Eye Institute, UC Irvine"
                }, 
                "investigator": {
                    "last_name": "Sameh Mosaed, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "laurabaker@cizikeye.org", 
                    "last_name": "Laura Baker", 
                    "phone": "713-795-0768"
                }, 
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77030"
                    }, 
                    "name": "Robert Cizik Eye Clinic - Clinical Trials Unit"
                }, 
                "investigator": {
                    "last_name": "Robert Feldman, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "raths@u.washington.edu", 
                    "last_name": "Sue Rath", 
                    "phone": "206-897-4331"
                }, 
                "facility": {
                    "address": {
                        "city": "Seattle", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98104"
                    }, 
                    "name": "Dept. of Ophthalmology, University of Washington Medical Center"
                }, 
                "investigator": {
                    "last_name": "Raghu Mudumbai, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Phase IIA Double-Masked Randomized Sham-Controlled Trial of QPI-1007 Delivered by a Single Intravitreal Injection to Subjects With Acute Primary Angle-Closure Glaucoma (APACG)", 
        "overall_contact": {
            "email": "jlynn@quarkpharma.com", 
            "last_name": "Judith Lynn"
        }, 
        "overall_official": {
            "affiliation": "Quark Pharmaceuticals", 
            "last_name": "Avner Ingerman, M.D., MSc.", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Vietnam: Ministry of Health", 
                "Singapore: Health Sciences Authority"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Safety and tolerability of a single intravitreal (IVT) dose of QPI-1007 as assessed by adverse events (AE)", 
                "safety_issue": "Yes", 
                "time_frame": "Day 0 (after injection) through Month 4. Systemic serious AEs (SAEs) assessed as related to study drug and all ocular SAEs Month 4 to Month 6 after injection"
            }, 
            {
                "measure": "Safety and tolerability of a single IVT dose of QPI-1007 as assessed by laboratory evaluations", 
                "safety_issue": "Yes", 
                "time_frame": "Screening, Day 1, and Month 4 after injection"
            }, 
            {
                "measure": "Safety and tolerability of a single IVT dose of QPI-1007 as assessed by vital signs and weight", 
                "safety_issue": "Yes", 
                "time_frame": "Weight: Screening and Month 4; Vital signs: Screening, Days 0 (before injection), 1 and 7, and Month 4 to 6"
            }, 
            {
                "measure": "Safety and tolerability of a single IVT dose of QPI-1007 as assessed by ophthalmic evaluations, Best Corrected Visual Acuity (BCVA) using Early Treatment Diabetic Retinopathy Study (EDTRS) chart and slit lamp exams (anterior & posterior segment)", 
                "safety_issue": "Yes", 
                "time_frame": "Screening, Days 0, 1 and 7, and Month 1 to 6"
            }, 
            {
                "measure": "Safety and tolerability of a single IVT dose of QPI-1007 as assessed by ophthalmic evaluations, Visual Field (VF) and Spectral Domain Optical Coherence Tomography (SD-OCT)", 
                "safety_issue": "Yes", 
                "time_frame": "Days 0 and 7, and Month 1 to 6"
            }, 
            {
                "measure": "Safety and tolerability of a single IVT dose of QPI-1007 as assessed by ophthalmic evaluation intraocular pressure (IOP)", 
                "safety_issue": "Yes", 
                "time_frame": "Screening, Days 0 (before injection, both eyes; after injection study eye only), 1 and 7, and Month 1 to 6"
            }, 
            {
                "measure": "Safety and tolerability of a single IVT dose of QPI-1007 as assessed by ophthalmic evaluation, Fundus Photographs (FP)", 
                "safety_issue": "Yes", 
                "time_frame": "Days 0 and 7, and Month 4"
            }, 
            {
                "measure": "Safety and tolerability of a single IVT dose of QPI-1007 as assessed by ophthalmic evaluations optic nerve head stereo photographs and contrast sensitivity", 
                "safety_issue": "Yes", 
                "time_frame": "Days 0 and 7, and Month 4 and 6"
            }, 
            {
                "measure": "Safety and tolerability of a single IVT dose of QPI-1007 as assessed by use of concomitant treatments", 
                "safety_issue": "Yes", 
                "time_frame": "Days 0, 1 and 7, and Month 1 to 6"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01965106"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "QPI-1007 pharmacokinetics (PK) parameters as assessed by the peak plasma concentration (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "Pre-injection, 1, 4 and 24 hours after injection, and 7 days after injection"
            }, 
            {
                "measure": "QPI-1007 pharmacokinetics (PK) parameters as assessed by the time to peak plasma concentration (Tmax)", 
                "safety_issue": "No", 
                "time_frame": "Pre-injection, 1, 4 and 24 hours after injection, and 7 days after injection"
            }, 
            {
                "measure": "Difference between QPI-1007 and control group (sham) as assessed by the prevalence of the abnormal visual fields", 
                "safety_issue": "No", 
                "time_frame": "4 months after injection"
            }, 
            {
                "measure": "Difference between QPI-1007 and control group (sham) as assessed by change in the mean deviation compared to baseline", 
                "safety_issue": "No", 
                "time_frame": "4 months after injection"
            }, 
            {
                "measure": "Difference between QPI-1007 and control group (sham) as assessed by progression of the visual fields compared to baseline", 
                "safety_issue": "No", 
                "time_frame": "4 months after injection"
            }, 
            {
                "measure": "Difference between QPI-1007 and control group (sham) as assessed by change in the mean BCVA using the EDTRS chart compared to baseline", 
                "safety_issue": "No", 
                "time_frame": "4 months after injection"
            }, 
            {
                "measure": "Difference between QPI-1007 and control group (sham) as assessed by SD-OCT parameters", 
                "safety_issue": "No", 
                "time_frame": "4 months after injection"
            }, 
            {
                "measure": "Difference between QPI-1007 and control group (sham) as assessed by change in the mean contrast sensitivity compared to baseline", 
                "safety_issue": "No", 
                "time_frame": "4 months after injection"
            }
        ], 
        "source": "Quark Pharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Quark Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}